Gatifloxacin

Gatifloxacin

Clinical data
ATC code	J01MA16 (WHO) S01AX21 (WHO)
Pharmacokinetic data
Protein binding	20%
Elimination half-life	7 to 14 hours
Identifiers
IUPAC name 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid
CAS Number	112811-59-3
PubChem CID	5379
DrugBank	APRD00996
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H22FN3O4
Molar mass	375.394 g/mol

WikiDoc Resources for Gatifloxacin
Articles
Most recent articles on Gatifloxacin Most cited articles on Gatifloxacin Review articles on Gatifloxacin Articles on Gatifloxacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Gatifloxacin Images of Gatifloxacin Photos of Gatifloxacin Podcasts & MP3s on Gatifloxacin Videos on Gatifloxacin
Evidence Based Medicine
Cochrane Collaboration on Gatifloxacin Bandolier on Gatifloxacin TRIP on Gatifloxacin
Clinical Trials
Ongoing Trials on Gatifloxacin at Clinical Trials.gov Trial results on Gatifloxacin Clinical Trials on Gatifloxacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Gatifloxacin NICE Guidance on Gatifloxacin NHS PRODIGY Guidance FDA on Gatifloxacin CDC on Gatifloxacin
Books
Books on Gatifloxacin
News
Gatifloxacin in the news Be alerted to news on Gatifloxacin News trends on Gatifloxacin
Commentary
Blogs on Gatifloxacin
Definitions
Definitions of Gatifloxacin
Patient Resources / Community
Patient resources on Gatifloxacin Discussion groups on Gatifloxacin Patient Handouts on Gatifloxacin Directions to Hospitals Treating Gatifloxacin Risk calculators and risk factors for Gatifloxacin
Healthcare Provider Resources
Symptoms of Gatifloxacin Causes & Risk Factors for Gatifloxacin Diagnostic studies for Gatifloxacin Treatment of Gatifloxacin
Continuing Medical Education (CME)
CME Programs on Gatifloxacin
International
Gatifloxacin en Espanol Gatifloxacin en Francais
Business
Gatifloxacin in the Marketplace Patents on Gatifloxacin
Experimental / Informatics
List of terms related to Gatifloxacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar®. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy.

Side-effects and removal from the market

A Canadian study published in the New England Journal of Medicine in March 2006 claims Tequin® can have "life threatening" side effects including serious diabetes. An editorial by Dr. Jerry Gurwitz in the same issue called for the Food and Drug Administration (FDA) to consider giving Tequin® a black box warning. This editorial followed distribution of a letter dated February 15 by Bristol-Myers Squibb to health care providers indicating action taken with the FDA to strengthen warnings for the medication. Subsequently it was reported on May 1, 2006 that Bristol-Myers Squibb would stop manufacture of Tequin, end sales of the drug after existing stockpiles were exhausted, and return all rights to Kyorin.

Gatifloxacin is now only available in the US as an opthalmic solution.

Notes

Template:QuinoloneAntiBiotics Template:SIB th:กาติฟลอกซาซิน